Literature DB >> 17086506

Cardiac resynchronization therapy in chronic heart failure.

Christian Sticherling1, Beat Schaer, Martin Coenen, Michael Kühne, Peter Ammann, Stefan Osswald.   

Abstract

Cardiac resynchronisation therapy (CRT) has emerged as a treatment option for patients with severe, drug-refractory heart failure and signs of intraventricular dyssynchrony. In clinical trials CRT reduced the overall mortality, improved symptoms, exercise tolerance, and left ventricular function, as compared with optimised medical therapy alone. One of the challenging fields in patient selection for CRT is to identify the 20-30% of heart failure patients with bundle branch block that will not respond to this novel therapy. Other fields of uncertainty, such as CRT in patients with atrial fibrillation or chronic right ventricular stimulation as well as the role of a back-up defibrillator will be discussed.

Entities:  

Mesh:

Year:  2006        PMID: 17086506     DOI: 2006/39/smw-11597

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  2 in total

1.  Clustering follow-up time-series recorded by cardiac implantable devices.

Authors:  M Guéguin; E Roux; A I Hernández; F Porée; P Mabo; L Graindorge; G Carrault
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2007

2.  Upregulation of leptin pathway correlates with abnormal expression of SERCA2a, phospholamban and the endothelin pathway in heart failure and reversal by CPU86017.

Authors:  T Na; D Z Dai; X Y Tang; Y Dai
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-02-08       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.